Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...

Zepbound is a prescription injectable medication that’s used for weight loss. You or a caregiver can administer it as a subcutaneous injection into your stomach or thigh. A caregiver can also ...

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...

Injection site reactions are the most common side effect of Emgality. The most frequent injection site reaction is pain. But there are steps you can take to help prevent or reduce pain from Emgality ...

Madison, Wis.-based UW Health’s virtual injection classes teach patients how to self-administer medications at home to keep them out of clinics for nonemergency procedures due to COVID-19. Once a drug ...

Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III OCARINA II trial evaluating Ocrevus® (ocrelizumab) ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...